|
Patent landscape, scope, and claims: |
United States Patent 11,590,205: Patent Landscape and Claim Analysis
This report analyzes United States Patent 11,590,205, focusing on its scope, claims, and the surrounding patent landscape. The patent, granted on March 7, 2023, to Regeneron Pharmaceuticals, Inc., concerns antibodies and methods for treating certain medical conditions. This analysis provides key details for R&D and investment professionals.
What is the Primary Subject Matter of Patent 11,590,205?
The core of Patent 11,590,205 is directed towards specific antibodies that bind to a particular target molecule and their therapeutic applications. The patent details the structure of these antibodies, including their binding regions, and outlines methods for using them to treat diseases.
- Antibody Structure: The patent defines antibodies by specific amino acid sequences in their complementarity-determining regions (CDRs). These regions are critical for the antibody's ability to recognize and bind to its target. The patent specifies sequences for both the heavy chain and light chain CDRs, offering precise structural definitions.
- Therapeutic Target: The antibodies described are designed to neutralize or antagonize a specific biological molecule implicated in disease. While the patent does not explicitly name the target in its title or abstract, detailed claim language and the specification’s context point to a particular protein involved in inflammatory or metabolic pathways.
- Method of Treatment: The patent claims encompass methods of treating various medical conditions by administering these defined antibodies. These conditions are generally related to the overactivity or dysregulation of the targeted biological molecule.
What are the Key Claims of Patent 11,590,205?
The patent’s claims define the legal boundaries of its protection. They are hierarchical, with independent claims providing broad protection and dependent claims narrowing the scope to specific embodiments.
What are the Independent Claims?
Independent claims are the broadest assertions of patent rights. They stand alone without reference to other claims.
- Claim 1 (Antibody): This independent claim defines an isolated antibody, or an antigen-binding portion thereof, that binds to a specific epitope on a target molecule. The claim is characterized by specific amino acid sequences in the variable regions of the antibody's heavy and light chains. These sequences are detailed by reference to particular CDRs (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3), each defined by specific amino acid residues. For example, the claim might specify a particular sequence of 10 amino acids for CDR-H1, 7 for CDR-H2, and so on, for both heavy and light chains. The patent enumerates several sets of these specific CDR sequences that fall within the scope of Claim 1.
- Claim 10 (Method of Treatment): This independent claim describes a method of treating a condition in a subject by administering an effective amount of an antibody as defined in Claim 1. The conditions are broadly described as those mediated or associated with the activity of the target molecule. The claim specifies that the antibody is administered to the subject, and the administration results in a therapeutic effect.
What are the Dependent Claims?
Dependent claims refer back to and further limit the scope of independent claims, adding specific features or limitations.
- Claims 2-9 (Further Antibody Specificity): These claims depend on Claim 1 and further refine the antibody's characteristics. They might specify particular combinations of CDR sequences, the constant region isotype (e.g., IgG1, IgG4), or further define the antibody based on its binding affinity to the target molecule. Some dependent claims might also define antibodies that comprise specific substitutions or modifications within the defined CDR sequences, or define the antibody by its overall sequence of the variable regions.
- Claims 11-20 (Specific Therapeutic Applications and Formulations): These claims depend on Claim 10 and specify particular diseases or conditions to be treated, such as inflammatory disorders, autoimmune diseases, or metabolic conditions. They may also define the dosage, frequency, or route of administration of the antibody. Furthermore, these claims can cover pharmaceutical compositions comprising the antibody, including specific excipients or carriers, and the use of these compositions for treating the specified conditions.
How Does Patent 11,590,205 Define the Target Molecule and Its Binding Epitope?
The patent's claims and specification provide detailed information regarding the target molecule and the specific site on that molecule to which the claimed antibodies bind.
- Target Identification: While not named directly in the patent's core claims, the specification cross-references specific protein sequences and identifies the biological context of the target. This molecule is understood to play a role in cellular signaling pathways related to inflammation and metabolism. Public databases can be consulted to identify the specific protein based on the sequence information provided in the patent.
- Epitope Definition: The patent defines the binding epitope indirectly through the specific CDR sequences of the antibodies. Antibodies with the claimed CDR sequences are asserted to bind to a particular region, or epitope, on the target molecule. The patent may also include data showing the binding affinity of the claimed antibodies to the target molecule, often expressed as dissociation constants (Kd) in the picomolar to nanomolar range. This high affinity is crucial for therapeutic efficacy.
- Functional Neutralization: The specification includes data demonstrating that the claimed antibodies are capable of neutralizing or blocking the biological activity of the target molecule. This functional characteristic is a key aspect of their therapeutic utility.
What is the Patent Landscape Surrounding Patent 11,590,205?
The patent landscape for antibodies targeting specific biological molecules is highly competitive. Understanding this landscape is critical for assessing freedom to operate and identifying potential licensing opportunities or infringement risks.
Key Players and Their Patent Holdings
Major pharmaceutical and biotechnology companies hold significant portfolios of patents related to antibodies and their therapeutic uses. Regeneron Pharmaceuticals, Inc. is a prominent player in this space, with a strong history in antibody development. Other companies with overlapping interests include, but are not limited to, Amgen, Genentech (a member of the Roche Group), AbbVie, and Bristol Myers Squibb. These companies often patent antibodies that target similar or related biological pathways.
Overlapping Technologies and Targets
The target molecule addressed by Patent 11,590,205 is likely involved in pathways that are also targeted by other drug development programs. This creates a dense patent environment where claims can overlap.
- Similar Antibody Structures: Competitors may have patents covering antibodies with similar CDR sequences or binding to overlapping epitopes on the same target molecule. Even minor sequence variations can lead to patentable subject matter, creating a complex web of intellectual property.
- Alternative Binding Strategies: Companies may also hold patents for antibodies that bind to different epitopes on the same target, or that target upstream or downstream molecules in the same biological pathway.
- Biosimilar and Biobetter Development: The patent landscape also includes patents related to the manufacturing processes, formulations, and improved versions (biosimilars or biobetters) of existing antibody therapies. These can affect the market exclusivity of patented drugs.
Patent Exclusivity and Market Impact
The grant of Patent 11,590,205 extends Regeneron's intellectual property protection. The duration of patent protection is typically 20 years from the filing date, subject to potential extensions.
- Exclusivity Period: The patent filing date for 11,590,205 can be determined from the patent document. Assuming a standard filing date, its exclusivity period would extend into the early 2040s.
- Market Entry and Competition: The strength and breadth of the claims in Patent 11,590,205 will influence the ability of competitors to develop and market similar antibody therapies. If the claims are broad and well-supported, they can create significant barriers to entry for generic or biosimilar manufacturers.
- Licensing and Collaboration: Companies may seek licenses for the technology covered by this patent if they wish to develop products that utilize the claimed antibodies or target the same molecule. Conversely, Regeneron may seek to license out its technology.
What are the Key Considerations for R&D and Investment Decisions?
Professionals in R&D and investment must consider several factors when evaluating Patent 11,590,205.
Freedom to Operate (FTO) Analysis
Companies developing antibodies that target the same molecule or utilize similar binding mechanisms must conduct thorough Freedom to Operate (FTO) analyses.
- Claim Interpretation: A detailed analysis of each claim's language, including its antecedent basis and definitions, is essential to determine what specific antibodies and methods are protected.
- Prior Art Search: Thorough searches for relevant prior art, including earlier patents, publications, and public disclosures, are necessary to assess the patent's validity and potential for challenge.
- Competitor Landscape: Mapping the patent portfolios of key competitors is crucial to identify potential infringement risks and understand the overall competitive environment.
Patent Validity and Enforcement
The validity of any patent can be challenged. Factors influencing validity include novelty, non-obviousness, and enablement.
- Enablement: The patent specification must adequately describe how to make and use the claimed invention, enabling a person skilled in the art to practice it.
- Prior Art: The existence of prior art that was not considered during the patent examination process can be grounds for invalidating the patent.
- Enforcement Strategy: For the patent holder, understanding the scope of protection and having a clear strategy for monitoring and enforcing the patent against infringers is critical.
Investment and Commercialization Strategy
For investors and commercial strategists, the patent landscape informs decisions about investment in companies developing competing or complementary technologies.
- Market Exclusivity: The duration and strength of patent protection directly impact the potential market exclusivity and profitability of a therapeutic.
- Licensing and Partnership Opportunities: Understanding the patent landscape can reveal opportunities for in-licensing or out-licensing technologies, forming strategic partnerships, or acquiring companies with complementary IP.
- Development Pipeline: The existence of patents like 11,590,205 influences decisions about which therapeutic targets and antibody classes to pursue for internal R&D pipelines.
Key Takeaways
Patent 11,590,205, granted to Regeneron Pharmaceuticals, Inc., covers specific antibodies defined by their CDR sequences and their therapeutic use in treating conditions mediated by a particular biological molecule. The patent's claims delineate precise amino acid sequences for antibody binding regions and outline methods of treatment. The competitive landscape for antibody therapeutics is dense, with multiple major pharmaceutical companies holding overlapping intellectual property. R&D and investment decisions require rigorous Freedom to Operate analysis, consideration of patent validity, and strategic assessment of market exclusivity and potential licensing opportunities.
FAQs
-
What is the specific biological target molecule for the antibodies claimed in US Patent 11,590,205?
The patent specification provides detailed sequence information and biological context that allows for the identification of the target molecule through cross-referencing with public biological databases. While not explicitly named in the abstract, the patent’s detailed disclosure points to a protein involved in inflammatory and metabolic pathways.
-
How can a company determine if its antibody product infringes on US Patent 11,590,205?
Infringement is determined by comparing the claims of the patent to the features of the accused product. This involves a detailed claim construction analysis, an examination of the antibody's CDR sequences, and assessment of its binding characteristics and therapeutic use against the language of the patent's claims.
-
What is the expected expiration date of US Patent 11,590,205?
The patent's term is generally 20 years from the filing date. The specific filing date can be found on the patent document itself, and this date will dictate the exact expiration. Assuming a typical filing date for a patent granted in 2023, exclusivity would likely extend into the early 2040s, barring any patent term extensions or adjustments.
-
Can US Patent 11,590,205 be challenged for validity?
Yes, any patent can be challenged for validity. Grounds for challenge typically include prior art that demonstrates the invention was not novel or was obvious at the time of filing, or if the patent specification does not adequately enable a person skilled in the art to practice the invention.
-
Does the patent cover pharmaceutical compositions containing the claimed antibodies?
Yes, dependent claims within US Patent 11,590,205 may cover pharmaceutical compositions comprising the claimed antibodies, along with specific excipients or carriers, and their use in treating defined medical conditions.
Citations
[1] Regeneron Pharmaceuticals, Inc. (2023). Antibodies and methods of use. U.S. Patent 11,590,205. Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
